# KLOW and GLOW: what is in the peptide blends, and what is known about them > Source: https://peptidewellnessusa.com/learn/klow-glow-peptides/ > Learn · Blends > By PeptideWellness Editorial Team · Medically reviewed by Ksenia Petrushkina, PA-C, MPAS · Updated November 11, 2026 · 5 min read GLOW is a vial of three peptides: GHK-Cu, BPC-157 and TB-500. KLOW adds a fourth, KPV. Telehealth sellers offer both by prescription. No study in people has tested either blend, and the October 2026 HHS policy that lets pharmacies compound some of these peptides covers single peptides only. GLOW is three peptides mixed in one vial: GHK-Cu, BPC-157 and TB-500. KLOW is the same three plus a fourth, KPV. The names are sellers' names, not drug names, and no regulator recognizes either product. Telehealth sellers offer them as monthly prescriptions; [Live Vital](https://peptidewellnessusa.com/providers/live-vital/) lists both, and [RxPepsDirect](https://peptidewellnessusa.com/providers/rxpepsdirect/) sells KLOW [1][2]. No study in people has tested either blend. Each peptide in them has been studied on its own, mostly in animals and cells, and the human evidence for the four ranges from a few small studies to none at all. This page goes through what is in the vial, what that evidence is and where the blends stand under US law. ## What is in the vial | Peptide | In GLOW | In KLOW | What it is | Human evidence on its own | | --- | --- | --- | --- | --- | | [GHK-Cu](https://peptidewellnessusa.com/peptides/ghk-cu/) | Yes | Yes | A copper-binding tripeptide found in blood, used in skin creams | Small cosmetic skin trials, applied to the skin; none for injection | | [BPC-157](https://peptidewellnessusa.com/peptides/bpc-157/) | Yes | Yes | A synthetic 15-amino-acid peptide based on a stomach protein fragment | Three small uncontrolled studies | | [TB-500](https://peptidewellnessusa.com/peptides/tb-500/) | Yes | Yes | A fragment of thymosin beta-4 | None for the fragment; Phase II trials used the full protein | | [KPV](https://peptidewellnessusa.com/peptides/kpv/) | No | Yes | A three-amino-acid piece of the hormone alpha-MSH | None | Neither seller we checked publishes how much of each peptide is in its vial [1][2]. Without that, there is no way to compare one seller's KLOW with another's, or with the doses used in the animal studies the marketing draws on. ## Why sell them together The pitch for GLOW is skin and healing: GHK-Cu for skin, BPC-157 and TB-500 for tissue repair. KLOW adds KPV for inflammation. Each claim comes from the separate literature on each peptide, almost all of it in rodents and cell cultures. The blend itself is a product choice, not something a study arrived at. ## What the research on the combination shows Very little. We searched PubMed on 10 November 2026 for any paper naming BPC-157 together with TB-500 or thymosin beta-4, BPC-157 with GHK-Cu, or KPV with any of the other three. There were 13, 7 and 1 records respectively, almost all of them reviews, and none was a clinical trial in people [3]. Two papers come closest: - **A rat study** compared BPC-157, TB-500 and the two together on Achilles tendon repair. Both peptides helped the tendon heal by some measures. Giving them together added nothing over either one alone [4]. - **A chart review from one clinic** asked 16 people with knee pain how they felt after a peptide injection into the knee. Four had BPC-157 plus thymosin beta-4, and three of them reported relief. There was no control group and no standard measure of pain or function [5]. Nobody has studied GHK-Cu or KPV in combination with anything else, in animals or people [3]. Nor has anyone published whether the four peptides stay stable when they are mixed and stored together. ## The legal position Each peptide has its own status, and the blend inherits all of them. In October 2026 HHS said it would not take action against licensed pharmacies that compound six peptides, BPC-157, TB-500 and KPV among them, if they meet ten conditions [6]. One condition is that the product contains a single peptide. A blend does not qualify, whatever is in it. The policy also names routes: BPC-157 and TB-500 by injection under the skin or into muscle, but KPV only by mouth or on the skin [6]. An injectable KLOW therefore falls outside the policy three ways: it is a blend, it contains KPV for injection, and it contains GHK-Cu, which is not one of the six. GHK-Cu's own status splits by route. For use on the skin it is in FDA's Category 1, which lets pharmacies compound it while FDA evaluates it. For injection, the nomination was withdrawn in April 2026 and an FDA advisory committee is due to review it before the end of February 2027 [7]. Our [regulatory tracker](https://peptidewellnessusa.com/learn/peptide-regulatory-tracker/) follows each change. The HHS policy is a statement that enforcement will be withheld, published as a draft, and HHS can change it [6]. It does not approve any of these peptides, and FDA has not approved a single one of them as a drug. ## What to ask before buying - **How much of each peptide is in the vial?** A seller that cannot say is selling a name. - **Which pharmacy makes it, and which bulk manufacturer supplied each peptide?** Our [pharmacy disclosure list](https://peptidewellnessusa.com/learn/which-providers-name-their-pharmacy/) shows which sellers name theirs. - **Is there a certificate of analysis for the finished blend?** A certificate for each peptide does not show what the mixed vial contains. - **Could you take the peptides separately?** Single peptides by the named routes are the form the HHS policy covers. For each peptide alone, see [BPC-157](https://peptidewellnessusa.com/peptides/bpc-157/), [TB-500](https://peptidewellnessusa.com/peptides/tb-500/), [GHK-Cu](https://peptidewellnessusa.com/peptides/ghk-cu/) and [KPV](https://peptidewellnessusa.com/peptides/kpv/); for the two most common partners, [BPC-157 vs TB-500](https://peptidewellnessusa.com/peptides/compare/bpc-157-vs-tb-500/). ## Frequently asked ### What is KLOW peptide? A blend of four peptides in one vial: GHK-Cu, BPC-157, TB-500 and KPV. It is a seller's product name, not an approved drug, and no study in people has tested it [1][3]. ### What is GLOW peptide? The same blend without KPV: GHK-Cu, BPC-157 and TB-500 [1]. ### What is the difference between KLOW and GLOW? KPV. KLOW contains it and GLOW does not. KPV has no published human data at all [3]. ### Is KLOW legal? No FDA route covers it. The October 2026 HHS policy for compounded peptides covers single peptides only, lists KPV for oral and topical use only and does not include injectable GHK-Cu [6][7]. ### Does KLOW work? There is no human study of the blend. A rat study of two of its parts, BPC-157 and TB-500, found that combining them added nothing over either alone [4]. ## References 1. [Live Vital. Treatments: Glow and Klow, monthly, "if prescribed". Read 26 October 2026.](https://livevital.io/treatments) 2. [RxPepsDirect. Peptides catalog: KLOW (BPC-157, TB-500, GHK-Cu and KPV). Read 28 October 2026.](https://rxpepsdirect.com/peptides) 3. [PubMed searches for BPC-157 with TB-500 or thymosin beta-4, BPC-157 with GHK-Cu, and KPV with BPC-157, GHK-Cu or TB-500, run 10 November 2026.](https://pubmed.ncbi.nlm.nih.gov/) 4. [Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. *Joint Dis Relat Surg.* 2026. PMID 42542926.](https://pubmed.ncbi.nlm.nih.gov/42542926/) 5. [Lee E. Intra-articular injection of BPC 157 for multiple types of knee pain. *Altern Ther Health Med.* 2021. PMID 34324435.](https://pubmed.ncbi.nlm.nih.gov/34324435/) 6. [HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Federal Register, FR Doc. 2026-22192, 91 FR 68526, 30 October 2026.](https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances) 7. [FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 and withdrawn nominations), content current 22 April 2026.](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) > Editorial note: Informational only — not medical advice. The seller menus were read on the dates shown and can change.